159981-19-8

Basic information

• Product Name: 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE
• Synonyms: 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE;6-(2,2,2-Trifluoroethoxy)nicotinaldehyde
• CAS NO: 159981-19-8
• Molecular Formula: C₈H₆F₃NO₂
• Molecular Weight: 205.13
• Mol File: 159981-19-8.mol

Chemical Properties

• Boiling Point: 239.8°C at 760 mmHg
• Flash Point: 98.9°C
• Appearance: /
• Density: 1.356g/cm³
• Vapor Pressure: 0.0392mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.97±0.22(Predicted)
• CAS DataBase Reference: 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE(159981-19-8)
• EPA Substance Registry System: 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE(159981-19-8)

Safety Data

• Hazard Codes: Xi
• Statements: 37/38-41-43
• Safety Statements: 26-36/37-39
• Hazardous Substances Data: 159981-19-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure and reactivity make it a valuable component in the development of new drugs, contributing to the creation of molecules with desired therapeutic properties.
Used in Organic Chemistry:
In the field of organic chemistry, 6-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE-3-CARBALDEHYDE is employed as a building block for the preparation of other organic compounds. Its special reactivity and stability, facilitated by the trifluoroethoxy group, allow for the synthesis of a wide range of molecules with potential applications in various industries, including materials science and agrochemicals.

InChI:InChI=1/C8H6F3NO2/c9-8(10,11)5-14-7-2-1-6(4-13)3-12-7/h1-4H,5H2

Upstream product

• 1373862-15-7 N-methoxy-N-methyl-6-(2,2,2-trifluoroethoxy)pyridine-3-carboxamide 
• 287979-27-5 6-(2,2,2-trifluoroethoxy)nicotinic acid methyl ester 
• 73781-91-6 6-Chloronicotinic acid methyl ester 

Relevant articles and documents

AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc

NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula -CR11R12-, -CO-, -CO-O-, or -CO-NH-, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.

ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS

The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.